Receptor status of breast cancer diagnosed during pregnancy: A literature review
[Display omitted] •Pregnancy-associated breast cancer (PABC) is reported to be frequently ER and PR negative and more often HER2 positive.•Breast cancer during pregnancy (BCdP) might differ from postpartum breast cancer, due to different hormonal influences.•We show BCdP to have an aggressive histop...
Gespeichert in:
Veröffentlicht in: | Critical reviews in oncology/hematology 2021-12, Vol.168, p.103494-103494, Article 103494 |
---|---|
Hauptverfasser: | , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 103494 |
---|---|
container_issue | |
container_start_page | 103494 |
container_title | Critical reviews in oncology/hematology |
container_volume | 168 |
creator | Bakhuis, Carsten F.J. Suelmann, Britt B.M. van Dooijeweert, Carmen Linn, Sabine van der Wall, Elsken van Diest, Paul J. |
description | [Display omitted]
•Pregnancy-associated breast cancer (PABC) is reported to be frequently ER and PR negative and more often HER2 positive.•Breast cancer during pregnancy (BCdP) might differ from postpartum breast cancer, due to different hormonal influences.•We show BCdP to have an aggressive histopathologic profile, distinct from similar-age control breast cancer patients.•We defined the ER, PR and HER2 status of BCdP for comparison with other PABC subgroups (e.g., postpartum patients).
The definition of PABC is inconsistently given as either breast cancer diagnosed exclusively during pregnancy, or combined with breast cancer diagnosed within six months to five years after delivery, and sometimes even longer. The longer away from the delivery date breast cancer is diagnosed, the less clear this association with pregnancy may become. Therefore, breast cancer diagnosed during pregnancy (BCdP) may not necessarily be the same disease entity as PABC. This review aims to provide an overview of BCdP receptor status, as this has not been assessed before. BCdP tumors were predominantly ER negative (56.6 %), PR negative (57.2 %) or both ER and PR negative (47.9 %). Moreover, HER2-overexpression was seen in 33.2 % of BCdP patients and 27.6 % had triple negative disease. This predominantly ER and PR negative profile with more often HER2 overexpression is aggressive and distinct from non-pregnant similar-aged patients, warranting future comparative research. |
doi_str_mv | 10.1016/j.critrevonc.2021.103494 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2590135996</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S104084282100281X</els_id><sourcerecordid>2590135996</sourcerecordid><originalsourceid>FETCH-LOGICAL-c374t-3cd107679b8323276b037750cc2abf4ecc3dbce201b4faeda2518a57d2f99e723</originalsourceid><addsrcrecordid>eNqFkMtOwzAQRS0EoqXwC8hLNil-JU7YlYqXVAmEYG059qRy1SbBdkD9e1y1wJLVjGbuncdBCFMypYQW16up8S56-OxaM2WE0VTmohJHaExLWWVEFPQ45USQrBSsHKGzEFaEECEKeYpGXEiac1qM0csrGOhj53GIOg4Bdw2uPegQsdGtAY-t08u2C2CxHbxrl7j3sGxTb3uDZ3jtIvhk9IDTOQ6-ztFJo9cBLg5xgt7v797mj9ni-eFpPltkhksRM24sJbKQVV1yxpksasKlzIkxTNeNAGO4rQ0wQmvRaLCa5bTUubSsqSqQjE_Q1X5u77uPAUJUGxcMrNe6hW4IiuUVoTyvqiJJy73U-C4ED43qvdtov1WUqB1PtVJ_PNWOp9rzTNbLw5ah3oD9Nf4ATILbvQDSr-l_r4JxkMBZ58FEZTv3_5ZviX2MxQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2590135996</pqid></control><display><type>article</type><title>Receptor status of breast cancer diagnosed during pregnancy: A literature review</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><creator>Bakhuis, Carsten F.J. ; Suelmann, Britt B.M. ; van Dooijeweert, Carmen ; Linn, Sabine ; van der Wall, Elsken ; van Diest, Paul J.</creator><creatorcontrib>Bakhuis, Carsten F.J. ; Suelmann, Britt B.M. ; van Dooijeweert, Carmen ; Linn, Sabine ; van der Wall, Elsken ; van Diest, Paul J.</creatorcontrib><description>[Display omitted]
•Pregnancy-associated breast cancer (PABC) is reported to be frequently ER and PR negative and more often HER2 positive.•Breast cancer during pregnancy (BCdP) might differ from postpartum breast cancer, due to different hormonal influences.•We show BCdP to have an aggressive histopathologic profile, distinct from similar-age control breast cancer patients.•We defined the ER, PR and HER2 status of BCdP for comparison with other PABC subgroups (e.g., postpartum patients).
The definition of PABC is inconsistently given as either breast cancer diagnosed exclusively during pregnancy, or combined with breast cancer diagnosed within six months to five years after delivery, and sometimes even longer. The longer away from the delivery date breast cancer is diagnosed, the less clear this association with pregnancy may become. Therefore, breast cancer diagnosed during pregnancy (BCdP) may not necessarily be the same disease entity as PABC. This review aims to provide an overview of BCdP receptor status, as this has not been assessed before. BCdP tumors were predominantly ER negative (56.6 %), PR negative (57.2 %) or both ER and PR negative (47.9 %). Moreover, HER2-overexpression was seen in 33.2 % of BCdP patients and 27.6 % had triple negative disease. This predominantly ER and PR negative profile with more often HER2 overexpression is aggressive and distinct from non-pregnant similar-aged patients, warranting future comparative research.</description><identifier>ISSN: 1040-8428</identifier><identifier>EISSN: 1879-0461</identifier><identifier>DOI: 10.1016/j.critrevonc.2021.103494</identifier><identifier>PMID: 34715316</identifier><language>eng</language><publisher>Netherlands: Elsevier B.V</publisher><subject>Aged ; Biomarkers, Tumor ; Breast cancer ; Breast Neoplasms - diagnosis ; Breast Neoplasms - epidemiology ; Estrogen receptor ; Female ; HER2 ; Humans ; Pregnancy ; Progesterone receptor ; Receptor, ErbB-2 - genetics ; Receptors, Estrogen - genetics ; Receptors, Progesterone ; Triple Negative Breast Neoplasms</subject><ispartof>Critical reviews in oncology/hematology, 2021-12, Vol.168, p.103494-103494, Article 103494</ispartof><rights>2021</rights><rights>Copyright © 2021. Published by Elsevier B.V.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c374t-3cd107679b8323276b037750cc2abf4ecc3dbce201b4faeda2518a57d2f99e723</citedby><cites>FETCH-LOGICAL-c374t-3cd107679b8323276b037750cc2abf4ecc3dbce201b4faeda2518a57d2f99e723</cites><orcidid>0000-0002-7155-3337 ; 0000-0001-8030-4335</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S104084282100281X$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65534</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34715316$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Bakhuis, Carsten F.J.</creatorcontrib><creatorcontrib>Suelmann, Britt B.M.</creatorcontrib><creatorcontrib>van Dooijeweert, Carmen</creatorcontrib><creatorcontrib>Linn, Sabine</creatorcontrib><creatorcontrib>van der Wall, Elsken</creatorcontrib><creatorcontrib>van Diest, Paul J.</creatorcontrib><title>Receptor status of breast cancer diagnosed during pregnancy: A literature review</title><title>Critical reviews in oncology/hematology</title><addtitle>Crit Rev Oncol Hematol</addtitle><description>[Display omitted]
•Pregnancy-associated breast cancer (PABC) is reported to be frequently ER and PR negative and more often HER2 positive.•Breast cancer during pregnancy (BCdP) might differ from postpartum breast cancer, due to different hormonal influences.•We show BCdP to have an aggressive histopathologic profile, distinct from similar-age control breast cancer patients.•We defined the ER, PR and HER2 status of BCdP for comparison with other PABC subgroups (e.g., postpartum patients).
The definition of PABC is inconsistently given as either breast cancer diagnosed exclusively during pregnancy, or combined with breast cancer diagnosed within six months to five years after delivery, and sometimes even longer. The longer away from the delivery date breast cancer is diagnosed, the less clear this association with pregnancy may become. Therefore, breast cancer diagnosed during pregnancy (BCdP) may not necessarily be the same disease entity as PABC. This review aims to provide an overview of BCdP receptor status, as this has not been assessed before. BCdP tumors were predominantly ER negative (56.6 %), PR negative (57.2 %) or both ER and PR negative (47.9 %). Moreover, HER2-overexpression was seen in 33.2 % of BCdP patients and 27.6 % had triple negative disease. This predominantly ER and PR negative profile with more often HER2 overexpression is aggressive and distinct from non-pregnant similar-aged patients, warranting future comparative research.</description><subject>Aged</subject><subject>Biomarkers, Tumor</subject><subject>Breast cancer</subject><subject>Breast Neoplasms - diagnosis</subject><subject>Breast Neoplasms - epidemiology</subject><subject>Estrogen receptor</subject><subject>Female</subject><subject>HER2</subject><subject>Humans</subject><subject>Pregnancy</subject><subject>Progesterone receptor</subject><subject>Receptor, ErbB-2 - genetics</subject><subject>Receptors, Estrogen - genetics</subject><subject>Receptors, Progesterone</subject><subject>Triple Negative Breast Neoplasms</subject><issn>1040-8428</issn><issn>1879-0461</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkMtOwzAQRS0EoqXwC8hLNil-JU7YlYqXVAmEYG059qRy1SbBdkD9e1y1wJLVjGbuncdBCFMypYQW16up8S56-OxaM2WE0VTmohJHaExLWWVEFPQ45USQrBSsHKGzEFaEECEKeYpGXEiac1qM0csrGOhj53GIOg4Bdw2uPegQsdGtAY-t08u2C2CxHbxrl7j3sGxTb3uDZ3jtIvhk9IDTOQ6-ztFJo9cBLg5xgt7v797mj9ni-eFpPltkhksRM24sJbKQVV1yxpksasKlzIkxTNeNAGO4rQ0wQmvRaLCa5bTUubSsqSqQjE_Q1X5u77uPAUJUGxcMrNe6hW4IiuUVoTyvqiJJy73U-C4ED43qvdtov1WUqB1PtVJ_PNWOp9rzTNbLw5ah3oD9Nf4ATILbvQDSr-l_r4JxkMBZ58FEZTv3_5ZviX2MxQ</recordid><startdate>202112</startdate><enddate>202112</enddate><creator>Bakhuis, Carsten F.J.</creator><creator>Suelmann, Britt B.M.</creator><creator>van Dooijeweert, Carmen</creator><creator>Linn, Sabine</creator><creator>van der Wall, Elsken</creator><creator>van Diest, Paul J.</creator><general>Elsevier B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-7155-3337</orcidid><orcidid>https://orcid.org/0000-0001-8030-4335</orcidid></search><sort><creationdate>202112</creationdate><title>Receptor status of breast cancer diagnosed during pregnancy: A literature review</title><author>Bakhuis, Carsten F.J. ; Suelmann, Britt B.M. ; van Dooijeweert, Carmen ; Linn, Sabine ; van der Wall, Elsken ; van Diest, Paul J.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c374t-3cd107679b8323276b037750cc2abf4ecc3dbce201b4faeda2518a57d2f99e723</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Aged</topic><topic>Biomarkers, Tumor</topic><topic>Breast cancer</topic><topic>Breast Neoplasms - diagnosis</topic><topic>Breast Neoplasms - epidemiology</topic><topic>Estrogen receptor</topic><topic>Female</topic><topic>HER2</topic><topic>Humans</topic><topic>Pregnancy</topic><topic>Progesterone receptor</topic><topic>Receptor, ErbB-2 - genetics</topic><topic>Receptors, Estrogen - genetics</topic><topic>Receptors, Progesterone</topic><topic>Triple Negative Breast Neoplasms</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Bakhuis, Carsten F.J.</creatorcontrib><creatorcontrib>Suelmann, Britt B.M.</creatorcontrib><creatorcontrib>van Dooijeweert, Carmen</creatorcontrib><creatorcontrib>Linn, Sabine</creatorcontrib><creatorcontrib>van der Wall, Elsken</creatorcontrib><creatorcontrib>van Diest, Paul J.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Critical reviews in oncology/hematology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Bakhuis, Carsten F.J.</au><au>Suelmann, Britt B.M.</au><au>van Dooijeweert, Carmen</au><au>Linn, Sabine</au><au>van der Wall, Elsken</au><au>van Diest, Paul J.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Receptor status of breast cancer diagnosed during pregnancy: A literature review</atitle><jtitle>Critical reviews in oncology/hematology</jtitle><addtitle>Crit Rev Oncol Hematol</addtitle><date>2021-12</date><risdate>2021</risdate><volume>168</volume><spage>103494</spage><epage>103494</epage><pages>103494-103494</pages><artnum>103494</artnum><issn>1040-8428</issn><eissn>1879-0461</eissn><abstract>[Display omitted]
•Pregnancy-associated breast cancer (PABC) is reported to be frequently ER and PR negative and more often HER2 positive.•Breast cancer during pregnancy (BCdP) might differ from postpartum breast cancer, due to different hormonal influences.•We show BCdP to have an aggressive histopathologic profile, distinct from similar-age control breast cancer patients.•We defined the ER, PR and HER2 status of BCdP for comparison with other PABC subgroups (e.g., postpartum patients).
The definition of PABC is inconsistently given as either breast cancer diagnosed exclusively during pregnancy, or combined with breast cancer diagnosed within six months to five years after delivery, and sometimes even longer. The longer away from the delivery date breast cancer is diagnosed, the less clear this association with pregnancy may become. Therefore, breast cancer diagnosed during pregnancy (BCdP) may not necessarily be the same disease entity as PABC. This review aims to provide an overview of BCdP receptor status, as this has not been assessed before. BCdP tumors were predominantly ER negative (56.6 %), PR negative (57.2 %) or both ER and PR negative (47.9 %). Moreover, HER2-overexpression was seen in 33.2 % of BCdP patients and 27.6 % had triple negative disease. This predominantly ER and PR negative profile with more often HER2 overexpression is aggressive and distinct from non-pregnant similar-aged patients, warranting future comparative research.</abstract><cop>Netherlands</cop><pub>Elsevier B.V</pub><pmid>34715316</pmid><doi>10.1016/j.critrevonc.2021.103494</doi><tpages>1</tpages><orcidid>https://orcid.org/0000-0002-7155-3337</orcidid><orcidid>https://orcid.org/0000-0001-8030-4335</orcidid></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1040-8428 |
ispartof | Critical reviews in oncology/hematology, 2021-12, Vol.168, p.103494-103494, Article 103494 |
issn | 1040-8428 1879-0461 |
language | eng |
recordid | cdi_proquest_miscellaneous_2590135996 |
source | MEDLINE; Elsevier ScienceDirect Journals Complete |
subjects | Aged Biomarkers, Tumor Breast cancer Breast Neoplasms - diagnosis Breast Neoplasms - epidemiology Estrogen receptor Female HER2 Humans Pregnancy Progesterone receptor Receptor, ErbB-2 - genetics Receptors, Estrogen - genetics Receptors, Progesterone Triple Negative Breast Neoplasms |
title | Receptor status of breast cancer diagnosed during pregnancy: A literature review |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-17T21%3A06%3A44IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Receptor%20status%20of%20breast%20cancer%20diagnosed%20during%20pregnancy:%20A%20literature%20review&rft.jtitle=Critical%20reviews%20in%20oncology/hematology&rft.au=Bakhuis,%20Carsten%20F.J.&rft.date=2021-12&rft.volume=168&rft.spage=103494&rft.epage=103494&rft.pages=103494-103494&rft.artnum=103494&rft.issn=1040-8428&rft.eissn=1879-0461&rft_id=info:doi/10.1016/j.critrevonc.2021.103494&rft_dat=%3Cproquest_cross%3E2590135996%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2590135996&rft_id=info:pmid/34715316&rft_els_id=S104084282100281X&rfr_iscdi=true |